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Executive Summary 
 
The following describes a research study commissioned by Galderma to explore 
the development of guidelines for community pharmacists on how to assess and 
manage patients who present with acne. 
 
Background 
Acne vulargis (or simply acne) is an extremely common skin condition affecting up to 
85% of teenagers and which, for a small proportion of individuals, can persist into 
adulthood. The majority of patients have mild to moderate disease which is 
amenable to treatment with topical acne therapies. Community pharmacies have 
been advocated as a first port of call for minor ailments, which includes skin 
conditions such as acne. While acne treatments are available over-the-counter, 
there is an array of different products available which can lead to confusion amongst 
patients and pharmacy team members. Furthermore, acne can be associated with 
psychosocial co-morbidities and lead to problems such as scarring hence the 
importance of a holistic assessment to ensure that patients are effectively managed 
and referred, where appropriate, to other healthcare providers. 
 
There are currently no pharmacy-specific guidelines published in the public domain 
to support UK-based pharmacy teams in the assessment and management of those 
seeking advice and or treatment for acne. The purpose of the present study was, 
therefore, to develop and feasibility test such a guideline to help support pharmacy 
teams to appropriately assess and manage patients seeking advice on acne. 
 
Method 
The study was conducted in three separate phases: semi-structured interviews with 
consultant dermatologists; an online Delphi study; and, a quantitative evaluation. 
The semi-structured interviews were used to gather information for the 
development of the initial statements for the Delphi and the final phase was used to 
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evaluate, from the perspectives of community pharmacists and patients, the 
guideline developed from the Delphi. 
 
Results 
Interviews were conducted with five consultant dermatologists with an interest in 
acne. Emergent themes from these interviews were used, together with the 
literature, to develop the statements for the first round of the Delphi. A total of 49 
statements were developed relating to patient consulation (7), clinical management 
(10), treatment (4), referral (9), lifestyle factors (16) and monitoring (3).  
  
The Delphi was conducted for three rounds with 19 panellists representing an 
interprofessional mix of dermatologists, GPs with a special interest in dermatology, 
specialist dermatology nurses, community pharmacists with an interest in 
dermatology, and expert patients. The response rate was 79% (n=15/19) and stable 
for all three rounds. 
 
Consensus level was set at 80% summative of strongly agree and agree. This was 
achieved for 21 out of the 49 statements, relating to: patient consultation (2/7) ; 
clinical management (4/10) ; treatment (1/4) ; referral (7/9) ; lifestyle factors (4/16) ; 
and, monitoring (3/3). In many instances, there was strong sense among panellists 
that assessment of acne was a role for the pharmacist rather than suitably qualified 
non-pharmacist staff.  
 
The final guideline was evaluated in 9 community pharmacies on 35 patients seeking 
advice on acne. Though limited in size, the median rating for the helpfulness of the 
guideline was 4 out of 5 (interquartile range 4-4) which suggested that it potentially 
was of value to pharmacists. 
 
Conclusion 
The Delphi process, utilising an interprofessional expert group, was successfully used 
to create a novel pharmacy-specific guideline to support pharmacy teams when 
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dealing with patients seeking advice on acne. Although the guideline was piloted 
with a small number of pharmacies, it appeared to be of value though further work 
with a larger number of pharmacies and patients is required to more fully evaluate 
the usefulness and value of the tool. 
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INTRODUCTION 
In the United Kingdom (UK), a number of potential new roles for community 
pharmacists were outlined such as in England in the 2008 White Paper, Pharmacy in 
England.1 The White Paper also made clear that the Government was committed to 
increasing the number of medicines available for purchase through pharmacies to 
further strengthen pharmacists’ clinical advisory role in helping to facilitate effective 
self-care.  
 
One area in which pharmacists have a potentially important role is in supporting self-
care in the management of skin problems. Although limited, the available literature 
highlights patient preference for self-care over medical care with regard to skin 
problems. For instance, one qualitative exploration of why patients with 
undiagnosed skin problems sought advice in pharmacies, identified that the 
accessibility of professional advice, the potential for triage to GP care and the 
perceived minor nature of the problem, were some of the factors leading to 
patients’ choice of community pharmacy as the primary source of healthcare advice 
on their skin problem.2 
 
Acne vulgaris is the eighth most prevalent disease worldwide with around 9.4% of 
the world’s population affected.3 Furthermore, one European study of over 10,500 
individuals aged 15 to 24 year old demonstrated a prevalence of 57%.4 Acne mostly 
occurs in adolescence, reportedly affecting 95 to 100% and 83 to 85% of 16 to 17 
year old boys and girls respectively.5 The condition is characterised by non-inflamed 
lesions (open and closed comedones) together with inflamed lesions  (papules and 
pustules). In more severe cases, nodules and cysts, which represent more severe 
papules and pustules are also present. Acne severity is generally considered as either 
mild, moderate or severe and although there are no universally accepted grading 
systems, the Leeds Acne Grading Scale (which ranges from grade 1 (mild to 
moderate) to 8 (severe)) is often used to delineate disease severity.6  
 
A further complication of acne is scarring. Precise figures are not widely available, 
however, one study in over 2000 Brazilian 18 year old males, observed a prevalence 
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of 22%.7 In addition, acne is associated with considerable psychosocial impact: it has 
a negative effect on self-esteem,8 can lead to suicidal ideation,9 and may have an 
adverse effect on quality of life.10  These potential long term consequences highlight 
the need for effective treatment and management. 
 
Although the diagnosis of acne is relatively straightforward, due to its obvious 
presence, there is a wide array of over-the-counter (OTC) treatments available. As a 
consequence of their convenience and accessibility, community pharmacies are an 
ideal setting for acne patients to seek advice and treatment. Nevertheless, 
marketing surrounding OTC treatments and the social consequences of acne such, as 
embarrassment and shame, may result in patient demands or perceived preference 
which may influence the recommendations of pharmacy staff yet be inappropriate. 
Indeed, several studies in different settings have identified poor knowledge among 
sufferers with respect to the causes of acne and there is even some evidence that 
community pharmacists lack sufficient knowledge about the condition.1-15 
Current European acne guidelines do not consider the role of community pharmacy 
teams or provide any information on the use of OTC topical acne treatments16 yet a 
recent European survey of just over 3,000 individuals, aged 15 to 24, found that the 
most common source of acne treatment was an OTC product chosen with the help 
of a pharmacist.17 Similarly, in a telephone survey of 1,566 young French people, 
aged between 12 and 25, 51% had not sought medical help for their acne but 10% 
had sought the advice of a pharmacist.18 It is therefore important to ensure that 
pharmacists possess the necessary skills to assess and provide suitable management 
advice to those seeking treatment for acne. 
 
One means of supporting pharmacy teams when dealing with patients seeking 
advice about acne is the development of community pharmacy-specific guidelines. 
This would offer an opportunity to more clearly define the position of both 
pharmacists and OTC treatments in the acne patient pathway to:  
 
1. serve to improve the care of patients by enhancing the role of pharmacists in 
OTC management of acne or referral to other professionals 
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2. enable the development of standards for assessment of acne in clinical practice 
 
Therefore, the purpose of the present study was to use the Delphi process to 
develop, and feasibility test, consensus-based guidelines for the community 
pharmacy-based management of patients presenting with acne vulgaris and to 
explore the value of the guideline with practicising community pharmacists. 
Aim 
To develop a guideline on community pharmacy assessment and management of 
acne vulgaris and to evaluate the usefulness of the guideline in practice. 
Objectives 
1. To utilise the expertise of consultant dermatologists to inform guideline 
development 
2. To determine agreement amongst experts on the content of the guideline, 
specifically around: 
a. The severity of acne to be managed in community pharmacy  
b. The most appropriate management options for community pharmacy 
c. The criteria for referral of patients from community pharmacy to their 
GP 
d. The impact of various lifestyle factors on acne severity 
3. To evaluate the usefulness of the guideline from the perspective of  
community pharmacists. 
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METHODS 
Design 
This study was a mixed methods design comprising three distinct phases: qualitative 
interviews; a consensus-based Delphi study and an evaluation of the developed 
guideline in practise. 
Phase 1 
Design 
Semi structured interviews. 
 
Setting 
Secondary care consultant dermatologists, based in England, with an interest in the 
management of acne vulgaris. 
 
Recruitment 
Potential dermatologists were identified by a member of the research team with 
expertise in acne (AML). A total of five individuals were selected and approached to 
participate in the interviews. 
 
Semi-structured telephone interviews were conducted with these five 
dermatologists by the same member of the research team (RT). This phase was 
primarily conducted to aid the development of the statements for the planned 
Delphi, hence data saturation was not a consideration. Interviewees were provided 
with full study information (Appendix A) and informed consent (Appendix B) was 
obtained by the researcher prior to conducting the telephone interview. 
A topic guide for the interviews was developed and reviewed by members of the 
research team and piloted with one dermatologist, not included in the final analysis 
(see Appendix C). Questioning focused on pharmacists’ assessment of acne, 
potential treatment options, criteria for referral to a GP and the impact of lifestyle 
factors on acne severity.   
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Analysis 
Interviews were audio recorded, transcribed verbatim and analysed thematically 
using NVivo 11 software (QSR International) to facilitate data management.  
 
Phase 2 
Design 
Consensus-based Delphi study. 
 
There are three main consensus methods: nominal group technique19, Delphi20 and  
the consensus development conference.21  The Delphi technique is appropriate for 
the development of guidelines or policies where there is limited evidence22 and 
typically comprises a series of rounds whereby agreement between panel members 
is determined anonymously. The viewpoints of all panel members and consensus 
levels were fed back iteratively upon the conclusion of each round in an effort to 
refine statements towards further consensus.  A six-point Likert scale was used for 
participants to rate levels of agreement with statements (strongly agree to strongly 
disagree). This scale was used to determine consensus and although different 
definitions of consensus have been reported in the literature, there is no agreement 
on the most appropriate level.23 Given the lack of current guidance on the 
community pharmacy management of acne and the potential importance of such a 
guideline, a level of agreement was arbitrarily set at 80% (summative strongly agree 
and agree) for each of the statements.  
 
Setting 
The study was conducted online. 
 
Statement development 
The statements for the Delphi were developed based on information derived from 
the dermatologist interviews also the existing research and guideline literature . 
These were reviewed by members of the team for readability then ‘think aloud’ and 
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pilot tested with one dermatologist independent of the research team. The final 
version of the statements were uploaded in SurveyMonkey® and the study 
conducted online to facilitate effective communication. 
 
Recruitment 
Members of the research team contacted potential panel members, making use of 
professional networks to identify specialists with an interest in acne who in turn 
were able to identify expert patients. Ideally, the aim was to recruit a panel of 20; 
five doctors, five pharmacists, five nurses and five expert patients. All who were 
approached agreed to join the Delphi panel. Each panel member was sent, via email, 
a participant information sheet (Appendix D) detailing study specifics and a consent 
form. Panel members were asked to sign and initial the consent form (Appendix E) if 
they agreed to participate and return it to the research team.  
 
Delphi rounds process 
At the start of the process, each panel member was sent an email with a link to the 
online Delphi questionnaire. A two week deadline was set for panel members to rate 
their level of agreement with each statement. An open comments box was provided 
alongside each statement, allowing members to justify their responses, where they 
felt it necessary, and the opportunity to add any additional comments.  
 
The second round included only those statements which had not achieved consensus 
in round one. Alongside each round two statement were the collated anonymous 
open comments  provided by panel members from the first round . As with the first 
round, a two week deadline was set for completion and return of responses and the 
level to determine consensus maintained, 80% (summative of strongly agree and 
agree). 
 
The third and final round proceeded as in the second round and, if no further 
consensus was achieved, the statements were deemed as non-agreement.  
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Panel members received a £50 fee for participation in each of the Delphi rounds up 
to a maximum of £150. 
 
Analysis 
Data collected after the initial round was exported from SurveyMonkey © into 
Microsoft Excel and then SPSS version 24 (IBM SPSS Statistics) for descriptive 
analysis (frequencies and percentages) to determine whether or not consensus had 
been achieved for each of the statements. A content analysis approach to the open 
text responses was agreed between two members of the research team, performed 
by one and sample checked for confirmation by the other member of the research 
team.24 
Phase 3 
Design 
Quantitative evaluation. 
 
Based on results of the Delphi study, the research team developed a guide on the 
assessment and management of patients who present with acne to be used in 
community pharmacy. One member of the team drafted the guideline and this was 
circulated to the others for review and modification. A copy of the final guideline can 
be found in Appendix F. 
 
The final guideline consisted of a single page of statements that included only those 
for which consensus was achieved in the Delphi. The statements were categorized 
into “patient assessment”, “patient treatment”, “self-care” and “referral to the GP”.  
In an effort to help community pharmacy staff to recognise the level of acne severity 
that was appropriate for management in the community pharmacy, the guideline 
included (with permission) the first 4 images from the Leeds Acne Severity Scale.1 
The guideline specified that community pharmacy management was appropriate for 
only grades 1 to 3 and the fourth image served to help teams identify the level of 
disease severity that warranted GP referral. 
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Setting 
Nine community pharmacies in the South West of the UK (Cornwall and Devon). 
 
Recruitment 
The clinical research network (CRN) circulated information on the study to 
community pharmacies within their database, asking for expressions of interest. 
 
In order to provide some feedback on the value of the guideline, community 
pharmacists were asked to complete an evaluation form for each of the patients 
who they encountered seeking advice on acne. The form (see Appendix G) recorded 
the following information: 
 
1. Patient demographics (i.e., gender, date of birth, years with acne) 
2. Type of acne present (i.e. comedonal, inflammatory, mixed, extent) 
3. Treatment provided by the community pharmacist 
4. If referral to the GP was warranted, the reason for referral, i.e. evidence of 
scarring, psychosocial co-morbidities, multiple treatment failure, truncal acne 
5. Community pharmacists were also asked to record how useful they had 
found the guideline when dealing with the patient, on a scale from 1 to 5, 
where 1 represented “not very helpful” and 5 “very helpful” 
 
Analysis 
Data from the evaluation forms were input to SPSS version 24 (IBM SPSS Statistics 
for Mac) for descriptive analysis (frequencies and percentages). 
Governance approvals  
The study was approved by the Ethical Review Panel at the School of Pharmacy & 
Life Sciences, Robert Gordon University, the Office for Research Ethics Committee 
Northern Ireland (ORECNI) and by the Health Research Authority (HRA). 
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RESULTS 
Phase 1 
All five dermatologists who were approached agreed to participate in the telephone 
interviews which lasted for approximately 25 minutes. The participating 
dermatologists had been qualified for between 20 and 29 years.  
 
Analysis of the interview data generated several main themes and associated sub-
themes which are given in Tables 1 to34. 
 
Table 1.  ‘Patient assessment’ as an area for inclusion plus details to include 
Area Patient assessment 
Details Illustrative quotes and dermatologist identifier 
Use of a 
photographic 
assessment scale 
The pictures [on the Leeds scale] … are really helpful because you can get the patient to 
grade themselves (D1) 
If they [pharmacists] can get familiar with the Leeds scale, it’s a visual scale, so you can 
have a look at the patient, have a look at the pictures that grade the acne and then make a 
guess-timate”(MD4) 
Types of lesions 
present 
They [pharmacists] ought to be able to distinguish between non-inflamed lesions, inflamed 
lesions and larger nodular lesions. Because if they’re going to advise about treatments, they 
need to know whether [lesions] are mainly comedonal or inflammatory (D2) 
Spot count, so the number of papules and pustules you have (D4) 
Impact of the acne They [pharmacists] should be focusing on the psychological impact, impact on daily 
functioning (D4) 
Need to ask about the quality of life, how they feel about what’s going on with their acne 
(D5) 
Extent of the 
disease 
[Assess] the areas of the body that are affected, so does it affect the chest, back and face 
(D3) 
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Table 2. ‘Over the counter treatment’  as an area for inclusion plus details to 
include 
Area Over the counter treatment 
Details Illustrative quotes  
Benzoyl peroxide 
(BPO) 
Benzoyl peroxide is a fantastic agent, it’s under-utilized because of the irritancy and the 
bleaching effect but it’s a very effective agent (D3) 
I tend to use it [BPO] for almost everybody … benzoyl peroxide would be something that is 
safe in pregnancy so that’s an issue compared to other topical treatments. (D4) 
Salicylic acid There are some studies that have demonstrated that salicylic acid has some benefits in the 
comedonal lesions... if you’ve got very mild disease you might want to start off with 
salicylic acid (D5) 
Salicylic acid may be very good if they’ve [patients] got a lot of comedones, it can help 
unblock the comedones so if they’ve got bumps, sand paper acne, that sort of thing that 
might be helpful (D2) 
Nicotinamide It’s certainly got a role if they’ve more inflammatory acne then that [nicotinamide]might be 
helpful (D1) 
I personally don’t use it because I’ve not found it very useful (D5) 
Cosmetic 
acceptability 
It’s about being something that’s cosmetically acceptable to the patient, something that 
isn’t going to sting, be actually sticky, something that’s pleasant to use (D3) 
It [the vehicle] needs to be something that patients find that they can rub into their skin, 
that’s pleasant to use that’s not sticky…doesn’t leave any kind of visible residue on the skin 
(D4) 
Duration of therapy If patients have responded by 6 to 8 weeks then they were going to respond to some 
degree, if they hadn’t it was unlikely that they were going to respond to that agent (D3) 
Use of emollients They can use an emollient as well [as acne therapy] often at the opposite end of the day so 
I normally recommend a non-comedogenic moisturiser (D4) 
 
 
There was agreement among the five dermatologists that community pharmacists 
should refer patients with: 
 Scarring 
 Widespread or severe disease 
 Treatment failure 
 Psychosocial co-morbidity 
Other factors mentioned included a family history of acne, early-onset (before the 
age of 12) disease and those with a high level of seborrhoea (very greasy skin). 
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Table 3. ‘Lifestyle modification’ as an area for inclusion plus details to include  
Area Lifestyle modification 
Details Illustrative quotes 
Diet If you look at the strength of evidence they’re moderate for glycaemic index and milk but they’re 
low for other foodstuff so I think those are the two things we might advise them about (D3) 
There is some evidence that high carbohydrate diets [high glycaemic index diet], may have an 
effect on acne, it’s not a very strong effect...and the same with dairy produce (D1) 
Smoking There may be some correlations between current comedonal acne in mature women with a 
history of smoking but otherwise we haven’t found any clear correlation (D3) 
Smoking definitely makes acne worse. So I would ask about smoking and say it’s a good idea to 
think about stopping or cutting down at least (D5) 
Stress There’s been a lot of work looking at stress…my observation is that we definitely see young 
people who seem to get deteriorations around the times of exams, I think stress does play a part 
(D3) 
I think stress is an issue, emotional stress does play a factor in worsening [acne](D4) 
Cosmetics We tend to go for oil-free, non-comedogenic properties and there are a lot of them about (D3) 
It’s important to ensure that the make-up is some kind of non-oil based, non-greasy and women 
should avoid comedogenic make-ups (D4) 
Sunlight We know short term that ultraviolet light can help but long term that doesn’t have an impact 
(D3) 
In terms of actually improving the acne, it [sunlight] can disguise acne to some extent but it’s 
generally not advised because of the risk of skin cancer (D1) 
Sleep  There is a couple of papers that have looked at that [sufficient sleep] but there’s only a little bit 
[of evidence] for it (D3) 
Humid 
environments 
Saunas and steam rooms and facials are generally not great for acne (D5) 
If they’re sweating a lot and humid environments and that sort of thing [is bad for acne] (D2) 
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Phase 2  
A series of 49 statements were developed for the first round based on information 
gathered from the dermatologist interviews in Phase 1. Statements were grouped 
into six categories: patient consultations (7 statements); clinical management (10 
statements); treatment (4 statements); referral (9 statements); lifestyle modification 
(16 statements); and monitoring (3 statements).   
 
Nineteen experts participated in the Delphi including: eight doctors (five consultant 
dermatologists; three dermatology specialist GPs); three pharmacists with an 
interest in dermatology; four dermatology specialist nurses; and four patients.  
 
Participation across the three rounds is shown in Table 4 although one panelist 
(patient) did not respond to any of the rounds. Fifteen people from the total panel of 
nineteen participated in each of the three rounds of the Delphi (but not the same 
fifteen each time).  The majority of respondents across round 1 were doctors (n=6) 
and each of the remaining rounds, nurses (n=4) and doctors (n=5).   
 
Table 4. Delphi participant distribution across the three rounds 
Delphi 
participants 
Round 1 – n (%) Round 2 – n (%) Round 3 – n (%) 
Patients 3 (20.0) 3 (20.0) 3 (20.0) 
Nurses 4 (26.7) 4 (26.7) 4 (26.7) 
Pharmacists 2 (13.3) 3 (20.0) 3 (20.0) 
Doctors 6 (40.0) 5 (33.3) 5 (33.3) 
 
As shown in Table 5, consensus (at least 80% summative of strongly agree and agree) 
was achieved for 21/49 statements. 
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Table 5. Delphi statements achieving consensus 
Statements which achieved consensus St
ro
ng
ly
 d
isa
gr
ee
 (n
) 
Di
sa
gr
ee
 (n
) 
So
m
ew
ha
t d
isa
gr
ee
 (n
) 
So
m
ew
ha
t a
gr
ee
(n
) 
Ag
re
e 
(n
) 
St
ro
ng
ly
 a
gr
ee
 (n
) 
%
 C
on
se
ns
us
 
Statements relating to patient consultations (2 out of 7) 
Acne consultations should be recorded on the pharmacy medication 
records (n=15, Round 2) 
0 2 1 0 7 5 80.0 
Pharmacists should consult with acne patients in a private 
consultation room (n=15, Round 2) 
0 0 0 1 3 11 93.3 
Statements relating to clinical management (4 out of 10) 
Pharmacists should assess the clinical severity of acne prior to 
managing with over-the-counter treatments (n=15, Round 1) 
2 0 0 1 5 7 80.0 
Pharmacists should only manage mild/moderate acne with over-
the-counter treatments (n=15, Round 1) 
2 1 0 0 2 10 80.0 
Based on the pictorial guide, pharmacists should only manage 
mild/moderate acne (n=15, Round 1) 
1 0 1 0 4 9 86.7 
Pharmacists should assess the number and type of acne lesions 
prior to managing with over-the-counter treatments (n=15, Round 
2) 
0 1 1 1 3 9 80.0 
Statements relating to referral (7 out of 9) 
Patients with evidence of scarring should be referred to a GP (n=15, 
Round 1) 
0 1 1 0 4 9 86.7 
Patients with psychological and social comorbidities (e.g. 
depression, anxiety or suicidal ideation) should be referred to a GP 
(n=15, Round 1) 
0 0 0 0 2 13 100 
Patients who have tried multiple over-the-counter treatments 
without success should be referred to a GP (n=15, Round 1) 
0 0 1 1 5 8 86.7 
Patients with moderate/severe acne should be referred to a GP 
(n=15, Round 1) 
0 0 1 2 1 11 80.0 
Patients with larger acne lesions (cysts or nodules) should be 
referred to a GP (n=15, Round 1) 
0 0 1 1 2 11 86.7 
Patients with early-onset acne (less than 12 years of age) should be 
referred to a GP (n=15, Round 2) 
0 0 1 2 3 9 80.0 
Patients with truncal acne should be referred to a GP (n=15, 
Round 2) 
0 0 1 1 7 6 86.7 
contd. 
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Table 5 (contd). Delphi statements achieving consensus 
 
The statements for each area not achieving consensus are shown in Table 6. 
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Statements relating to treatment (1 out of 4) 
Patients should be offered a choice of  formulation (e.g.  lotions, 
gels or creams) that they find cosmetically acceptable (n=15, Round 
1) 
0 0 0 2 4 9 86.7 
Statements relating to advice (4 out of 16) 
Pharmacists should advise against the use of ultraviolet treatments 
(n=15, Round 1) 
0 0 1 2 6 6 80.0 
Suitably-trained non-pharmacist pharmacy staff should advise 
against the use of ultraviolet treatments (n=15, Round 1) 
1 0 1 1 6 6 80.0 
Pharmacists should advise acne patients to use oil-free, non-
comedogenic (e.g. does not block pores) make-up products (n=15, 
Round 1) 
0 1 0 2 4 8 80.0 
Suitably-trained non-pharmacist pharmacy staff should advise acne 
patients to use oil-free, non-comedogenic (e.g. does not block 
pores) make-up products (n=15, Round 1) 
1 0 0 1 4 9 86.7 
Statements relating to monitoring (3 out of 3) 
Patients should be advised to continue with topical acne treatments 
for at least 6 weeks unless they experience severe adverse effects 
(n=15, Round 1) 
1 1 0 1 2 10 80.0 
Patients should be warned about the bleaching effects of benzoyl 
peroxide (e.g. bedding, clothing) (n=15, Round 1) 
1 0 0 0 2 12 93.3 
Patients with acne should be advised to use an oil-free, non-
comedogenic emollient alongside their topical treatment (n=15, 
Round 3) 
0 0 0 2 7 6 86.7 
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Table 6. Statements not achieving consensus 
contd.  
Statements not achieving consensus (n=15, Round 3) St
ro
ng
ly
 d
isa
gr
ee
 (n
) 
Di
sa
gr
ee
 (n
) 
So
m
ew
ha
t d
isa
gr
ee
 (n
) 
So
m
ew
ha
t a
gr
ee
(n
) 
Ag
re
e 
(n
) 
St
ro
ng
ly
 a
gr
ee
 (n
) 
%
 C
on
se
ns
us
 
Statements relating to patient consultations (5 out of 7) 
Suitably-trained non-pharmacist staff should consult with 
acne patients in a private consultation room  
3 3 2 3 0 4 26.7 
Pharmacists should assess the psychological and social 
impact of acne prior to managing it with over-the-counter 
treatments 
1 2 1 2 2 7 60.0 
Suitably-trained non-pharmacists should assess the 
psychological and social impact of acne prior to managing it 
with over-the-counter treatments  
3 4 2 2 0 4 26.7 
Pharmacists should assess the impact of a patients’ acne on 
their quality of life prior to managing it with over-the-
counter treatments  
1 3 1 3 1 6 46.7 
Suitably-trained non-pharmacists should assess the impact of 
a patients’ acne on their quality of life prior to managing it 
with over-the-counter treatments 
3 5 1 2 0 4 26.7 
Statements relating to clinical management (6 out of 10) 
Suitable-trained non-pharmacist staff should assess the 
clinical severity of acne prior to managing with over-the-
counter treatments  
3 5 2 1 0 4 26.7 
Suitable-trained non-pharmacist staff should assess the 
number and type of acne lesions prior to managing with 
over-the-counter treatments  
4 5 1 1 0 4 26.7 
Suitable-trained non-pharmacist staff should only manage 
mild/moderate acne with over-the-counter treatments 
2 4 0 1 3 5 53.3 
Pharmacists should use a pictorial guide to assess the 
severity of a patients’ acne 
0 0 0 4 4 7 73.3 
Suitable-trained non-pharmacist staff should use a pictorial 
guide to assess the severity of a patients’ acne  
5 3 2 0 1 4 33.3 
Based on the pictorial guide, suitable-trained non-pharmacist 
staff should only manage mild/moderate acne 
3 5 0 2 1 4 33.3 
19 | P a g e  
 
Table 6 (contd). Statements not achieving consensus 
contd. 
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Statements relating to referral (2 out of 9) 
Patients with a family history of acne should be referred to a 
GP 
6 0 1 2 3 3 40.0 
 Patients with very greasy skin (seborrhoea) should be 
referred to a GP 
1 1 4 2 6 1 46.7 
Statements relating to treatment (3 out of 4) 
Benzoyl peroxide is a suitable first-choice treatments for all 
patients unless they have a known hypersensitivity to the 
drug  
0 2 0 5 5 3 53.3 
Nicotinamide can be used as a second-line treatment for 
patients who fail to respond adequately to benzoyl peroxide  
1 9 1 0 3 1 26.7 
Salicylic acid should be offered to those with very mild 
comedonal acne 
0 8 0 4 1 2 20.0 
Statements relating to advice (12 out of 16) 
Pharmacists should advise acne patients to adopt a healthy 
diet 
0 5 1 2 3 4 46.7 
Suitable-trained non-pharmacist staff should advise acne 
patients to adopt a healthy diet 
3 4 0 1 4 3 46.7 
Pharmacists should advise acne patients to avoid foods with 
a high glycaemic index (e.g. Biscuits, cakes, white bread) 
2 3 1 3 3 3 40.0 
Suitable trained non-pharmacist staff should advise acne 
patients to avoid foods with a high glycaemic index (e.g. 
Biscuits, cakes, white bread) 
3 4 0 2 3 3 40.0 
Pharmacists should advise acne patients to reduce or stop 
smoking 
1 0 1 6 3 4 46.7 
Suitable-trained non-pharmacist staff should advise acne 
patients to reduce or stop smoking  
1 1 1 6 2 4 40.0 
Pharmacists should advise acne patients to avoid 
saunas/steam rooms/facials 
2 3 5 1 2 2 26.7 
Suitable-trained non-pharmacist staff should advise acne 
patients to avoid saunas/steam rooms/facials  
2 3 4 2 1 3 26.7 
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Table 6 (contd). Statements not achieving consensus 
 
Panelist comments 
As shown in Tables 7 to 9, panelists often had differing views on statements, and the 
value of the interventions described in the statements, with respect to advice and 
management of acne. The quotes are not attributed to a given panelist as no 
attempt was made to track their participation. 
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Pharmacists should advise acne patients to try and reduce 
their stress (e.g. work-related, personal)  
0 4 1 5 3 2 33.3 
Suitably-trained non-pharmacist pharmacy staff should 
advise acne patients to try and reduce their stress (e.g. work-
related, personal) 
2 3 2 4 2 2 26.7 
Pharmacists should advise acne patients on the importance 
of sufficient sleep 
0 4 1 4 3 3 40.0 
Suitably trained non-pharmacist pharmacy staff should 
advise acne patients on the importance of sufficient sleep 
1 4 2 3 3 2 33.3 
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Table 7. ‘Patient assessment’ area with supporting quotes 
 
Table 8. ‘Over-the-counter’ area with supporting quotes 
 
  
Area Patient assessment 
Details Supporting quotes 
Psychological assessment It is a significant ask for a pharmacist to be making this [psychosocial] assessment. 
I don’t think that this [psychological assessment] should be the responsibility of the non-
pharmacist staff. 
Patients will not always feel comfortable in bringing up this topic, and so it is important for a 
pharmacist to initiate this conversation and do an assessment. 
Clinical management Clinical assessment should be carried out by a pharmacist [rather than pharmacy staff] due 
to further training and expertise. 
If a person requires treatment advice and support, they should be seen by a pharmacist. 
Suitably trained non-pharmacist staff should only give OTC advice on mild acne - definitely 
not moderate, which should be referred to the pharmacist. 
GP referral Clearly this [family history] is one marker for potentially more troublesome acne, but by no 
means the only one and doesn't have that [GP referral] sort of mandate. 
Yes [referral] if the patient has tried a few different OTC treatments without success. 
A useful marker [seborrhoea] of the likelihood that the acne is going to be more resistant / 
troublesome. 
Pictorial guide As a guide [images of acne], but not used as a complete decision aid. Must consider whole 
presentation & other contributing factors. 
[a pictorial guide] is only really for monitoring progress once the goals of treatment have 
been established by someone more suitably qualified. 
Area Over-the-counter treatment 
Details Illustrative quotes 
 Benzoyl peroxide Clearly need to be advised HOW to use and side-effects etc.  Excellent, non-antibiotic first-
line option. 
[good first-line treatment] providing that the patient starts with a low concentration then 
builds up. 
Evidence points to topical retinoids which are POM so advice to consult GP is the next line 
of treatment [after benzoyl peroxide]. 
Nicotinamide Not a great treatment in my experience. 
I've not been too impressed by this [nicotinamide]. It is generally quite a weak alternative 
and is especially unlikely to be helpful if the acne has already failed to respond to a first-line 
option. 
 Salicylic acid There are better options [than salicylic acid] e.g. benzoyl peroxide and topical retinoids. 
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Table 9. ‘Lifestyle modification’ area with supporting quotes 
 
  
Area Lifestyle modification 
Details Illustrative quotes 
Dietary advice Dietary advice may be of benefit but it is important also for pharmacists to recognise that 
diet sometimes has no clear link to acne. 
Unsure if evidence re dietary link is strong enough to specifically target people with acne 
Need to ensure not fueling myths. 
They [pharmacists] could indicate the emerging evidence to support a low GI diet. 
Smoking Obviously all patients who smoke should receive this advice, but as its role in acne is not 
well established, I would not risk alienating the patient by raising this, unless asked. 
General health advice [around smoking] as no evidence that a link to acne. 
Facials/sauna Only if [facials/sauna] this is effecting their skin [should patients avoid]. 
I am sure patients would be appreciative of this more general advice [avoiding 
facials/saunas]. Patients may not have thought about these activities having an effect. 
Stress Again general wellbeing [advice], not necessarily acne-related. 
Very helpful in terms of acne management and for general wellbeing. 
Little evidence to support this advice. 
Sufficient sleep Very helpful in terms of acne management and for general wellbeing. 
All patient need sufficient sleep but no evidence just for acne. 
Generally not relevant - not worth focusing on. 
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Phase 3 
A total of 9 community pharmacists used the Delphi-derived guideline on a total of 
35 patients which comprised 11 (31.4%) males and 24 (68.6%) females, with an 
overall mean age of 22.6 years  (SD = 6.57) with a range 15 to 40 years.  
 
The onset of acne occurred at an average age of  14 years (range 11 to 29). The type 
of acne was comedonal only (37.1%, n = 35), inflammatory only (20%, n = 35) and a 
mixture of comedonal and inflammatory acne (40%, n = 35). One patient (2.9%, n= 
35)) was described as having both scarring and hyper pigmentation. The treatments 
provided by pharmacists are shown in Figure 1. 
 
 
Figure 1. Treatments provided by pharmacists (n = 35) 
*Pharmacists were able to supply more than one treatment 
In total, 19 patients (54.3%, n = 35) were referred to the GP because of their acne 
with the reasons for referral shown in Figure 2. 
0 10 20 30 40 50 60
Benzoyl peroxide wash
Benzoyl peroxide leave-on
Nicotinamide gel
Salicylic acid
% of cases*
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Figure 2. Reasons for acne referrals to a GP  
*Pharmacists could refer for more than one reason  
 
Pharmacists were asked to rate the usefulness of the guideline when treating those 
with acne on a 1 to 5 Likert scale, where 1 = not very helpful and 5 = very helpful. 
The median rating for all patients was 4 (interquartile range = 0). 
 
 
DISCUSSION 
 
Key findings 
Consensus was achieved for 21 of 49 statements. Since the Delphi was directed at 
the pharmacy team rather than the pharmacist, many of the statements sought 
consensus on the role of both pharmacists and what was termed “suitably qualified 
non-pharmacist staff”. However, the results showed how, for some statement 
categories, the low level of consensus was more a function of the person involved 
rather than the content of the statement. For instance, consensus was achieved for 
only four of the ten statements relating to clinical management, each of which was 
linked to the pharmacist performing the role. For the remaining six statements, all 
but one made reference to the use of “suitably qualified” non-pharmacist staff. In 
0 10 20 30 40 50 60 70
Presence of scarring
Psychosocial co-morbidity
Failure of OTC therapy
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other words, there was a strong sense that panelists – expert patients, doctors, 
nurses and pharmacists - felt clinical assessments should only be undertaken by a 
pharmacist. This was also apparent in relation to consultations with acne patients. 
Panellists agreed that pharmacists rather than non-pharmacist staff should conduct 
private consultations.  
Though consensus was achieved in some areas, the implications were somewhat 
contradictory and liable to generate confusion among pharmacy teams. For instance, 
although acne is known to be associated with suicidal ideation and social 
impairment,9 panelists did not agree that it was appropriate that pharmacy teams 
assess patients for signs of psychosocial co-morbidities and the impact of acne on 
quality of life. However, and in contrast, the panel were in agreement that 
individuals exhibiting psychosocial impairment should be referred to the GP despite 
a lack of agreement that such an assessment should be undertaken. As a result and 
to assist pharmacy teams, the guideline included signs and symptoms that were 
potentially indicative of psychosocial impairment. 
There was a low level of consensus for statements related to lifestyle modification, 
irrespective of whether it was a pharmacist or non-pharmacist practitioner. The 
sixteen lifestyle modification statements related to eight separate factors, of which 
consensus was only achieved for two (four in total), irrespective of who offered the 
advice. Consensus was likely to reflect the lack of convincing evidence that exposure 
to UV radiation, for instance sunlight29 or other forms of light therapy are effective in 
acne.30 Similarly, the need to advise on the use of non-comedogenic cosmetics arises 
from work which suggests that many of the common ingredients used in cosmetics 
are comedogenic and thus potentially able to aggravate acne.31 
The lack of consensus for other lifestyle modification may be indicative of the lack of 
robust data for the impact of these factors on acne. For instance, the role of diet 
remains controversial32 and evidence for the potential acnegenic effects of a high 
glycaemic index diet has come from several small scale trials, for instance Smith et 
al33 and cross-sectional observational work.34 Despite evidence of a possible link 
between stress and acne35 and an apparent positive association with disease 
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severity,36 panelists did not feel that the evidence was sufficient to recommend 
advice on reducing levels of stress to improve acne. The positive link between 
smoking and acne has arisen from epidemiological evidence37,38 although not all 
studies have detected such an association.39 There is also evidence that increases in 
humidity (which can lead to sweating e.g. saunas) can also worsen acne but the data 
are based on patient self-reporting and thus potentially unreliable.40 Finally, it has 
been suggested that lack of sleep triggers the release of stress hormones and since 
acne may be potentially made worse by stress, lack of sleep may indirectly worsen 
acne though the available evidence is circumstantial.41 
An important purpose of the Delphi was to establish consensus on the most 
appropriate first-line community pharmacy-based treatment for acne. Currently,  
pharmacy-based acne treatments in the UK are based on either benzoyl peroxide, 
nicotinamide or salicylic acid. Unfortunately, there was no consensus on a suitable 
first-line treatment which probably reflects the lack of good quality evidence that is 
available for either benzoyl peroxide,42 nicotinamide43 or wash products that contain 
salicylic acid.44 The only statement achieving consensus was on the importance of 
patient choice in selecting a suitable vehicle. It is assumed that offering patients a 
formulation that they find to be cosmetically acceptable will improved adherence 
and hence patient outcomes. Though patient preferences for a topical formulation 
have been shown to be similar between those with acne, eczema and psoriasis,45 in a 
large scale study of the factors affecting adherence in acne, cosmetic acceptability 
was not found to be an important factor.46  
Finally, there was a high level of consensus for statements (7/9) related to patient 
referral. Acne scarring occurs during resolution of lesions and can be a problem for 
up to 95% of people with acne.47 Furthermore, it is important to recognise the 
psychosocial impact of the condition which in the more severe cases can lead to 
suicidal ideation.48 There was consensus that GP referral was appropriate for 
patients with trunctal acne and this is based on the pragmatic view that it is 
inefficient and often difficult for an individual to self-treat large areas of acne with 
topical agents. 
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In an effort to evaluate the final guideline, it was used in 9 community pharmacies 
on a total of 35 patients. The overall helpfulness of the guideline, which was 
assessed for each patient, had a median score of 4 out of 5 (range 3 to 5) which 
possibly suggests that it might represent a useful tool when assessing patients 
seeking advice on acne.  
Strengths and limitations 
This appears to be the first time that the Delphi process has been used to develop a 
consensus-based guideline for the community pharmacy management and 
assessment of patients with acne. The Delphi process was found to be an effective 
tool for facilitating a “virtual” discussion amongst panelists and strengthened to 
some extent because of the multidisciplinary nature of members which allowed for a 
diversity of opinion and experience. The Delphi response rates were relatively high23  
(75%) and were stable across each of the three rounds.  The distribution of 
respondents across panel member professional category (dermatologist, general 
practitioner, specialist nurse, community pharmacist and expert patient) varied 
within each round and hence, any changes in agreement may be reflective of 
changes in the composition of the expert panel across each of the rounds.  As 
highlighted, there was diversity in the professional category of panel members 
although their distribution was uneven and therefore, some categories were 
underrepresented.  For example, both doctors and nurses comprised the largest 
proportions of both recruited panel members and responses.  The evaluation is 
limited in the sense that it is small scale, and hence, the findings are not 
generalisable.  It may be beneficial to evaluate the guideline on a larger scale to 
determine true effectiveness. 
CONCLUSION 
The present study successfully utilised the Delphi process for the development of a 
consensus-based guideline for the community pharmacy management of patients 
seeking advice on acne. Although consensus was achieved on criteria for assessment 
and referral, there was a lack of agreement upon a suitable first-line treatment 
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option or on advice related to lifestyle modification. There was also strong sense 
that the assessment of patients should be undertaken by community pharmacists 
rather than pharmacy staff.  
 
There was an appreciation of the final guideline when used in community pharmacy 
practice but, since this was based on a small number of pharmacies and patients, 
further work is clearly necessary to fully evaluate the utility of the guideline in a 
larger sample of community pharmacies and patients.  
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Appendix A 
 
 
Research team 
Professor Derek Stewart 
Dr Rod Tucker 
Dr Vibhu Paudyal 
Dr Katie Maclure 
Dr Alison Layton 
 
Developing and feasibility testing guidelines for the management of acne vulgaris 
in community pharmacy 
 
Dear Dermatologist 
 
You are being invited to take part in a research study.  Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. Thank you for reading this. 
 
What is the purpose of the study? 
The aim of the study is to develop a guideline to help community pharmacists 
manage patients who seek advice and treatment for acne.  
 
Why have I been chosen? 
You have been chosen because you are considered to be an expert in the 
management of acne. We want to interview you to get some idea of your thoughts on 
the the management of acne by patients who visit community pharmacies.  
 
Do I have to take part? 
Participation in the study is voluntary and your decision to participate will not 
influence your relationship with members of the research team. 
 
What will happen to me if I take part? 
You will be contacted by a member of the research team to take part in a telephone 
interview to seek your views on how you believe that acne should be managed in 
pharmacies.  
 
We would like to record your telephone conversation.  
 
What are the possible benefits of taking part? 
We cannot guarantee any direct benefit for you from participation in this study. 
However, interview data will inform the development of a questionnaire which will be 
sent to other experts in the subject area to develop guidelines through 
Delphi/consensus process for the community pharmacy management of acne.  
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Will my taking part in this study be kept confidential? 
Yes, your contact details will be kept secure at the university. You will not be named 
in any   report of the study. 
 
What will happen to the results of the research study? 
We hope that the main findings of the study will be published in a health care journal. 
You may request a copy of the publication or report by contacting Professor Derek 
Stewart (d.stewart@rgu.ac.uk).  
 
Who is organizing and funding the research? 
This project is organized by the research team and funded by the Galderma UK. 
   
Who has reviewed the study? 
 This study has been approved by the Robert Gordon University and an NHS ethics 
committee. 
 
If you are interested in participating in the study, please sign the enclosed 
consent form and return to us in the reply-paid envelope provided. 
Alternatively, you can sign and scan the enclosed form and email to Dr Vibhu 
Paudyal (v.paudyal1@rgu.ac.uk)  
 
Thank you in advance 
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Appendix B 
 
 
 
Dermatologist  Consent form 
 
Developing and feasibility testing guidelines for the management of acne vulgaris 
in community pharmacy 
 
Please initial each box 
 
I confirm that I have read and understand the information sheet 
dated 30th April 2016 and have had the opportunity to ask 
questions 
 
  
I understand that it is up to me whether or not I take part and that I 
am free to withdraw at any time, without giving any reason.  
 
 
 
I agree to take part in this study. 
 
 
 
Your Name  _______________________________________________ 
 
Signature  _______________________________________________ 
 
Date   _______________________________________________ 
 
The best telephone number to contact me on is 
 
  _______________________________________________ 
 
The best time of day to contact me is 
 
  _______________________________________________ 
 
 
 
Thank you for all your help 
Please return this form in the reply paid envelope 
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Appendix C 
 
 
 
Background 
 
• Can you tell me about where you work and your current role? 
• What do you enjoy most about your current role? [probe – do you have any 
dislikes?] 
• What other positions/roles have you held before your current post? 
 
Acne patients 
 
• What proportion of your workload do you think involves patients with acne? 
• What are the main factors or issues that you consider when you see a patient 
with acne for the first time?  
• What do you consider when assessing the impact of acne on a patient? [probe 
– is it only physical factors or are other factors important?] 
 
 
Acne patients in the pharmacy 
 
• Do you think that patients with acne should always try to treat themselves 
before seeking medical advice? 
 
• When a patient seeks advice about their acne in a pharmacy, what would 
you say are the main factors that a pharmacist should consider? 
 
Severity 
 
• What level of acne severity do you think is appropriate for pharmacists to 
manage?  
 
• How should pharmacists assess the severity of a patient’s acne? [probe – what 
things should they be looking for or asking about] 
 
Referral 
 
 
• What are the signs or symptoms that should prompt a pharmacist to refer a 
patient with acne to their GP? [probe - are these only physical or are there 
other factors that pharmacists should consider and ask about? 
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• Should they suggest an over-the-counter product first or simply refer the 
patient without any treatment?  
 
Management 
 
• What types of currently available over-the-counter treatments do you think 
would be appropriate to manage patients with acne? [probe – do you there is 
any value in using cosmetic washes?] 
 
• How long should pharmacists recommend that a patient perseveres with an 
over-the-counter acne treatment before trying something else 
 
• What are your thoughts on the availability of topical antibiotics for acne in 
some European countries?  
 
• What, if any, treatments do you think should be available through 
pharmacies?  
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Appendix D 
 
 
Research team 
Professor Derek Stewart 
Dr Rod Tucker 
Dr Vibhu Paudyal 
Dr Katie MacLure 
Dr Alison Layton 
 
Developing and feasibility testing guidelines for the management of acne vulgaris 
in community pharmacy 
 
Dear Panel member 
 
You are being invited to take part in a research study.  Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. Thank you for reading this. 
 
What is the purpose of the study? 
The aim of the study is to develop a guideline to help community pharmacists 
manage patients who seek advice and treatment for acne.  
 
Why have I been chosen? 
You have been chosen because you are considered to have some expertise in the 
management of acne. We want to get your views on the topics generated from the 
interviews undertaken with dermatologists on the level of acne severity appropriate 
for pharmacy management, criteria for referral of patients by pharmacists to their GP 
and the most suitable treatment options for acne available in pharmacies.  
 
Do I have to take part? 
Participation in the study is voluntary and your decision to participate will not 
influence your relationship with members of the research team. 
 
What will happen to me if I take part? 
You will be contacted by a member of the research team to take part in a Delphi 
panel. This will be delivered in an electronic format and you will be sent a series of 
statements related to the management of acne in the pharmacy and asked to state 
your level of agreement with these statements. The statements will be refined and 
new ones added and we expect that the whole process should be completed over a 
period of 6 weeks to complete the tasks.  
What are the possible benefits of taking part? 
We cannot guarantee any direct benefit for you from participation in this study though 
you will be helping to develop a guideline to be used by community pharmacists for 
patients who present seeking advice/treatment for their acne.  
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Will my taking part in this study be kept confidential? 
Yes, your contact details will be kept secure at the university. You will not be named 
in any   report of the study. 
 
What will happen to the results of the research study? 
We hope that the main findings of the study will be published in a health care journal. 
You may request a copy of the publication or report by contacting Professor Derek 
Stewart (d.stewart@rgu.ac.uk) 
 
Who is organizing and funding the research? 
This project is organized by the research team and funded by the Galderma UK 
   
Who has reviewed the study? 
 This study has been approved by the Robert Gordon University and an NHS ethics 
committee. 
 
If you are interested in participating in the study, please sign the enclosed 
consent form and return to us in the reply-paid envelope provided. 
Alternatively, you can sign and scan the enclosed form and email to Dr Vibhu 
Paudyal (v.paudyal1@rgu.ac.uk 
 
Thank you in advance 
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Appendix E 
 
Delphi participant Consent form 
 
Developing and feasibility testing guidelines for the management of acne vulgaris 
in community pharmacy 
 
Please initial each box 
 
I confirm that I have read and understand the information sheet 
dated 1st June 2016 and have had the opportunity to ask 
questions 
 
  
I understand that it is up to me whether or not I take part and that I 
am free to withdraw at any time, without giving any reason.  
 
 
 
I agree to submit my responses to the Delphi questions 
when requested by the research team.  
 
I understand that data collected during the study will be 
used for research purposes including publication of 
anonymised findings and quotations. I grant copyright 
permission on the understanding that my confidentiality 
will be protected.  
 
I agree to take part in this study.  
 
 
 
Your Name  _______________________________________________ 
 
Signature  _______________________________________________ 
 
Date   _______________________________________________ 
 
The best telephone number to contact me on is 
 
  _______________________________________________ 
 
The best time of day to contact me is 
 
  _______________________________________________ 
Thank you for all your help. Please return this form in the reply paid envelope 
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Appendix F 
 
Management of acne in community pharmacy 
 
This guide has been developed by an expert panel of dermatologists, pharmacists, 
nurses and patients and provides recommendations to assist community pharmacists 
in the management of acne.  
 
Patient assessment 
 
• Record all acne consultations on the pharmacy medication record 
• Consult with acne patients in a private consultation room 
• Assess the clinical severity of acne prior to managing with over-the-counter 
treatments  
 
Patient treatment 
 
• Only mild/moderate acne (grades 1 – 3 see images) should be managed with 
over-the-counter treatments  
• The number and type of acne lesions should be assessed prior to managing 
with over-the-counter treatments 
• A choice of formulation (e.g.  lotions, gels or creams) that is cosmetically 
acceptable to patients should be offered 
• Advise against the use of ultraviolet treatments  
• Warn about the bleaching effects of benzoyl peroxide (e.g. bedding, clothing) 
 
Self-care 
 
• Advise acne patients to use oil-free, non-comedogenic (e.g. does not block 
pores) make-up products 
 
Referral to the GP 
 
• Refer patients with evidence of scarring to a GP 
• Refer patients with psychological and social comorbidities (e.g. apparent low 
mood, acne affecting lifestyle etc) to a GP 
• Refer patients who have tried multiple over-the-counter treatments without 
success to a GP 
• Refer patients with moderate/severe acne (grade 4 and above) to a GP 
• Refer patients with larger acne lesions (cysts or nodules) to a GP 
• Refer patients with early-onset acne (less than 12 years of age) to a GP  
• Refer patients with truncal acne to a GP 
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*The revised Leeds acne grading system. O’Brien et al. J Dermatol Treat 1998;9: 215-220 
 
 
 
Grade 1* Grade 2 
Grade 3 Grade 4 REFER 
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Appendix G 
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